A Randomised, Open Label, Multi-centre, Phase III Study to Investigate the Efficacy of Bendamustine Compared to Treatment of Physician's Choice in the Treatment of Subjects With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab
Phase of Trial: Phase III
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Bendamustine (Primary) ; Antineoplastics
- Indications B cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms ROBIN
- Sponsors Mundipharma International
- 20 Jul 2017 Planned End Date changed from 1 Nov 2017 to 31 Oct 2018.
- 20 Jul 2017 Planned primary completion date changed from 1 Oct 2017 to 31 Oct 2018.
- 27 Mar 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2017.